Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib
Completed · Phase 3
Conditions studied: Gastrointestinal Stromal Tumors
In brief
The study evaluated the safety and efficacy of nilotinib versus current treatment in adults with gastrointestinal stromal tumors (GIST) who have either progressed or who were intolerant to the first and second line treatments.
Key facts
- Study ID
- NCT00471328
- Run by
- Novartis Pharmaceuticals
- People needed
- 248
- Starts
- 2007-03-01
- Expected to finish
- 2011-06-01
- Last updated by the study team
- 2012-06-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCLA's Jonsson Comprehensive Cancer Center — Los Angeles, California, United States
- Washington Hospital Center - Washington Cancer Institute — Washington D.C., District of Columbia, United States
- H. Lee Moffitt Cancer Center — Tampa, Florida, United States
- University of Chicago Hospital — Chicago, Illinois, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Wayne State University/Wertz Clinical Cancer Center — Detroit, Michigan, United States
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri, United States
- St. Vincent's Comprehensive Cancer Center — New York, New York, United States
- Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- University of Texas/MD Anderson Cancer Center — Houston, Texas, United States
- Novartis Investigative Site — Auchenflower, Queensland, Australia
- Novartis Investigative Site — East Melbourne, Victoria, Australia
- Novartis Investigative Site — Vienna, Austria
- Novartis Investigative Site — Toronto, Canada
- Novartis Investigative Site — Prague, Czechia
- Novartis Investigative Site — Bordeaux, France
- Novartis Investigative Site — Lyon, France
- Novartis Investigative Site — Marseille, France
- Novartis Investigative Site — Berlin, Germany
- Novartis Investigative Site — Cologne, Germany
- Novartis Investigative Site — Düsseldorf, Germany
- Novartis Investigative Site — Essen, Germany
- Novartis Investigative Site — Frankfurt, Germany
- Novartis Investigative Site — Hanover, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.